A07: Clandestine laboratories

Purpose of collecting these data:

This module aims at collecting information on detected clandestine laboratories to assist in obtaining an understanding of the scale and trends in illicit production and manufacture of drugs. Also, it allows for the identification of new drugs being illicitly manufactured in the country.

The aim of this module is to measure trends and the extent of production and manufacture of drugs, which have been identified by national authorities.

<table>
<thead>
<tr>
<th>Item</th>
<th>Type</th>
<th>Description</th>
<th>Response options</th>
<th>Definitions / Specific instructions</th>
<th>Disaggregation</th>
<th>Metadata</th>
<th>Justification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Item</td>
<td>Type</td>
<td>Description</td>
<td>Response options</td>
<td>Definitions / Specific instructions</td>
<td>Disaggregation</td>
<td>Metadata</td>
<td>Justification</td>
</tr>
</tbody>
</table>
| Existence of illicit manufacture of drugs | I | Illegal manufacturing of drugs during the reporting period | Yes, no, unknown | - Glossary  
- Guidelines will be developed on how to properly report information on this module, with examples and clear terminology. | Drug type: Heroin, Cocaine salts, coca base/cocaine paste, Amphetamine, Methamphetamine, Ecstasy-type substances, NPS, Hallucinogens, Precursors, Others (specify) | Information on the procedure used for the qualitative assessment: specify number of experts, affiliation, method (e.g. Delphi). Primary sources used for the qualitative assessment: national data (specify collection method) periodic government report (link) specific study (link) expert assessment other (specify) | EWG: Current ARQ questions were deemed as being too technical and detailed and it was suggested that detection of clandestine laboratories be kept as part of the annual component of the questionnaire. Experts highlighted the need for clearer terminology, further disaggregation, and improved metadata collection |
| Trends | I | Trends in number of labs detected | Large increase, Some increase, Stable, Some decrease, Large decrease, Unknown | - Glossary  
- Guidelines will be developed on how to properly report information on this module, with examples and clear terminology. | Drug type: Heroin, Cocaine salts, coca base/cocaine paste, Amphetamine, Methamphetamine, Ecstasy-type substances, NPS, Hallucinogens, Precursors, Others (specify) | Information on the procedure used for the qualitative assessment: specify number of experts, affiliation, method (e.g. Delphi). Primary sources used for the qualitative assessment: national data (specify collection method) periodic government report (link) specific study (link) expert assessment other (specify) | EWG: Current ARQ questions were deemed as being too technical and detailed and it was suggested that detection of clandestine laboratories be kept as part of the annual component of the questionnaire. Experts highlighted the need for clearer terminology, further disaggregation, and improved metadata collection |
| New developments in illicit manufacture of drugs | I | Production of new types of drugs in reporting period that never produced before  
Drugs that stopped being produced, possible reasons  
Major changes in the use of precursors or pre-precursors, specify if they are produced locally or imported. | Free text | - Glossary  
- Guidelines will be developed on how to properly report information on this module, with examples and clear terminology. | Drug type: Heroin, Cocaine salts, coca base/cocaine paste, Amphetamine, Methamphetamine, Ecstasy-type substances, NPS, Hallucinogens, Precursors, Others (specify) | Information on the procedure used for the qualitative assessment: specify number of experts, affiliation, method (e.g. Delphi). Primary sources used for the qualitative assessment: national data (specify collection method) periodic government report (link) specific study (link) expert assessment other (specify) | EWG: Current ARQ questions were deemed as being too technical and detailed and it was suggested that detection of clandestine laboratories be kept as part of the annual component of the questionnaire. Experts highlighted the need for clearer terminology, further disaggregation, and improved metadata collection |
| Clandestine labs detected | II | Number of labs detected by drug | Statistical data | - Each detected lab should be counted as one in “All drugs” row regardless of how many different types of drugs are produced  
- If more than one drug was believed to be produced in or associated with a single lab, should be counted under each drug.  
- The sum of the labs by drug may be higher than “All drugs” value | Drug type (list as defined above) | Time frame: Reporting year  
Geographical coverage: National / sub-national, specify  
All LEA involved in data collection and recording drug seizures in the country. | UNGASS 3d; 3h; 5d; 5l; 5m; |
| III | Number of labs detected by type | Statistical data | • Glossary  
• The sum of breakdown by type of labs must add up to the total number of labs per each drug | • Drug type (list as defined above)  
• By 2 main types:  
  - Drug manufactured, synthesised  
  - Tabletting, packaging, refining,  
  - Both  
  - Unknown | • Only those LEA whose data are included in the reported seizures |
| III | Number of laboratories detected by size | Statistical data | • Glossary  
• The sum of breakdown by size of labs must add up to the total number of labs per each drug | • Drug type (list as defined above)  
• By size – Kitchen labs (<50gr)/ small (50 gr - 500 gr) / medium (0.5kg - 50kg) / industrial (50+ kg), Unknown |
| Availability of studies / research / surveys | III | Link to any studies, reports, surveys or other research regarding production and manufacture of plant-based and synthetic drugs in the country in the last 5 years | Provide link | Not applicable | Not applicable |